表紙:世界の小児用ワクチン市場の予測:疾患別、企業別
市場調査レポート
商品コード
256208

世界の小児用ワクチン市場の予測:疾患別、企業別

Pediatric Vaccine Market, Global Forecast Infants Vaccinated, Vaccines Administered, Immunization, By Disease (Influenza, MMR, Pneumonia, Meningitis, Hepatitis, Tap, Hib, Polio) & Companies

出版日: | 発行: Renub Research | ページ情報: 英文 232 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.72円
世界の小児用ワクチン市場の予測:疾患別、企業別
出版日: 2018年07月03日
発行: Renub Research
ページ情報: 英文 232 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

小児用ワクチン市場は、2024年までに480億米ドルを上回ると予測されています。

当レポートでは、世界の小児用ワクチン市場について調査分析し、市場・人口シェア、ワクチン投与済みの小児人口、小児用ワクチンの投与件数のほか、疾患別分析、企業別分析、主要動向など、体系的な情報を提供しています。

第1章 調査結果

第2章 小児 (乳幼児) 用ワクチン市場

第3章 市場・人口シェア - 小児用ワクチン

  • 小児用ワクチンの市場シェア
  • ワクチン投与済み小児の人口シェア
  • 投与済み小児用ワクチンのシェア
  • ワクチン企業の市場シェア

第4章 ワクチン投与済みの小児人口

第5章 小児用ワクチンの投与件数

第6章 疾患別分析:小児 (乳幼児) 用ワクチン市場

  • インフルエンザ
  • MMR (麻疹・おたふく風邪・風疹)
  • 肺炎球菌
  • 髄膜炎菌
  • 肝炎
  • DTaP (ジフテリア・百日咳・破傷風)
  • ヘモフィラス・インフルエンザ菌タイプB (HIB)
  • 混合ワクチン
  • ポリオ
  • ロタウイルス
  • 水痘

第7章 疾患別分析:ワクチン投与済み小児 (乳幼児) 人口

  • インフルエンザ
  • MMR (麻疹・おたふく風邪・風疹)
  • 肺炎球菌
  • 髄膜炎菌
  • 肝炎
  • DTaP (ジフテリア・百日咳・破傷風)
  • ヘモフィラス・インフルエンザ菌タイプB (HIB)
  • 混合ワクチン
  • ポリオ
  • ロタウイルス
  • 水痘

第8章 疾患別分析:小児 (乳幼児) 用ワクチンの投与件数

  • インフルエンザ
  • MMR (麻疹・おたふく風邪・風疹)
  • 肺炎球菌
  • 髄膜炎菌
  • 肝炎
  • DTaP (ジフテリア・百日咳・破傷風)
  • ヘモフィラス・インフルエンザ菌タイプB (HIB)
  • ポリオ
  • ロタウイルス
  • 水痘

第9章 疾患別分析:予防接種プロファイル

  • 乳幼児の予防接種率 (%)
  • 世界の予防接種プロファイル
  • 地域の予防接種プロファイル
    • 麻疹:報告症例数
    • 流行性耳下腺炎 (おたふく風邪) :報告症例数
    • 風疹:報告症例数
    • 風疹 (CRS) :報告症例数
    • ジフテリア:報告症例数
    • 破傷風 (新生児) :報告症例数
    • 破傷風 (合計) :報告症例数
    • 百日咳:報告症例数
    • ポリオ:報告症例数
    • 黄熱病:報告症例数
    • 日本脳炎:報告症例数

第10章 主要企業のワクチン売上高

  • GlaxoSmithKline, plc.
  • Merck & Co.
  • Sanofi Pasteur
  • Pfizer, Inc.
  • 世界:その他の企業

第11章 ワクチン:製品とパイプライン

  • GSK
  • Merck
  • Sanofi
  • Pfizer

第12章 ワクチン産業における主なM&A

第13章 ワクチンと規制当局の介入

第14章 ワクチン市場の促進要因

第15章 ワクチン市場の課題

目次

Get Free Customization in This Report.

Pediatric Vaccine Market is projected to exceed US$ 48 Billion by the year 2024. Increasing government and non-government funding for the development of new vaccines, along with raising awareness about the benefits of vaccination, is certainly expected to positively drive the market growth in the coming years. In order to cut the healthcare expenses, governments have been making continuous efforts to reduce the cost of patient immunization through various vaccination programs funded by government or non-government health authorities. For example; several countries have included Children Vaccination Programs, which offers vaccines to children who lack health insurance or one who cannot afford the cost of vaccination.

Growing prevalence of chronic diseases is another major market driver, driving the market of infant (pediatric) vaccines. The immune system is not fully developed in infants, hence they are at a higher risk of contracting severe diseases and so, vaccination plays a significant role in their prevention. According to WHO; effective immunization activities have had a major impact on reducing measles deaths. It is found that measles vaccination prevented an estimated 20.4 million deaths across the globe. Global measles deaths have decreased by 84% from an estimated 550,100 in 2000 to 89,780 in 2016.

Renub Research report titled “Pediatric Vaccine Market, Global Forecast Infants Vaccinated, Vaccines Administered, Immunization, By Disease [Influenza, MMR (Measles, Mumps, and Rubella), Pneumonia, Meningitis, Hepatitis, Tap (Diphtheria, Tetanus, Pertussis), Haemophilus influenzae type B (Hib), Polio, Rotavirus, Varicella, and Combination Vaccine], Companies (GlaxoSmithKline, Merck, Sanofi, Pfizer, & Others)” provides a complete analysis of Global Pediatric (Infants) Vaccine Market.

By Disease - Pneumococcal Vaccine is likely to grow at Noteworthy Rate in the Forthcoming Years

The report studies the market of the following vaccine: Influenza, MMR (Measles, Mumps, and Rubella), Pneumonia, Meningitis, Hepatitis, Tap (Diphtheria, Tetanus, Pertussis), Haemophilus influenzae type B (Hib), Polio, Rotavirus, Varicella, and Combination Vaccine. Pneumococcal and Combination Vaccines together hold the significant market share in pediatric (infants) vaccine market and is expected to continue so during the forecast period.

Nearly 650 Million Vaccines Doses will be administered in Pediatrics (Infants) by the year 2024

As per our analysis; it is estimated that by the year 2024, the doses of vaccines administered will reach nearly 650 Million. The number of vaccine doses is expected to grow considerably during the forecast period due to growing awareness among the parents about the benefits of vaccines and also the developing countries around the world that now have included a number of vaccines to their national immunization programme as per WHO recommendations, which indeed will drive the pediatric vaccine market in recent years.

Regional - Immunization Profile

The report also comprises of the en-detail study of global and regional immunization profile: By Diseases such as Measles, Mumps, Rubella, Diphtheria, Tetanus, Polio and so on and By Regions such as Africa (AFR), Americas (AMR), Eastern Mediterranean (EMR), Europe (EUR), South-East Asia (SEAR), Western Pacific (WPR) and Global.

Company Analysis

GlaxoSmithKline, Merck, Sanofi, and Pfizer are some of the top companies that deal efficiently in vaccine business globally. These companies have been studied thoroughly in the report.

Global Pediatric (Infants) Vaccine Market has been extensively studied from 3 major points:

  • 1. Pediatrics Vaccines (Disease wise) Market & Forecast
  • 2. Number of Vaccinated Pediatric (Infants) (Disease wise) & Forecast
  • 3. Doses of Vaccines Administered in Pediatric (Infants) (Disease wise) & Forecast

Client can purchase this report in sections through Purchase by Chapter Tab given above.

This market research report provides a complete analysis of the Global Pediatric (Infants) Vaccine Market and their projections for the upcoming years, Growth Drivers, Challenges, and Disease wise number of reported cases.

By Disease

  • Influenza
  • MMR (Measles, Mumps, and Rubella)
  • Pneumonia
  • Meningitis
  • Hepatitis
  • Tap (Diphtheria, Tetanus, Pertussis)
  • Haemophilus influenzae type B
  • Polio
  • Rotavirus
  • Varicella
  • Combination Vaccine

Key Companies Covered in the Report

  • GlaxoSmithKline
  • Merck
  • Sanofi
  • Pfizer

Table of Contents

1. Research Findings

2. Pediatric (Infant) Vaccines Market (2011-2024)

3. Market & Numbers Share-Pediatric Vaccines

  • 3.1. Pediatric Vaccine Market Share
  • 3.2. Pediatric Vaccinated Population Share
  • 3.3. Pediatric Doses of Vaccines Administered Share
  • 3.4. Vaccine Companies Market Share

4. Pediatric Vaccinated Numbers

5. Pediatric Doses of Vaccines Administered

6. Disease wise-Pediatric (Infants) Vaccines Market (2011-2024)

  • 6.1. Influenza
  • 6.2. MMR (Measles, Mumps, and Rubella Vaccine)
  • 6.3. Pneumococcal
  • 6.4. Meningococcal
  • 6.5. Hepatitis
  • 6.6. DTaP
  • 6.7. Haemophilus Influenzae Type B (HIB)
  • 6.8. Combos (Combination)
  • 6.9. Polio
  • 6.10. Rotavirus
  • 6.11. Varicella

7. Disease wise-Numbers of Vaccinated Pediatric (Infants) (2011-2024)

  • 7.1. Influenza
  • 7.2. MMR
  • 7.3. Pneumococcal
  • 7.4. Meningococcal
  • 7.5. Hepatitis
  • 7.6. DTaP
  • 7.7. Hib (Haemophilus Influenzae Type B)
  • 7.8. Combos (Combination Vaccines)
  • 7.9. Polio
  • 7.10. Rotavirus
  • 7.11. Varicella

8. Disease wise-Doses of Vaccines Administered in Pediatric (Infants) (2011-2024)

  • 8.1. Influenza
  • 8.2. MMR
  • 8.3. Pneumococcal
  • 8.4. Meningococcal
  • 8.5. Hepatitis
  • 8.6. DTaP
  • 8.7. Hib (Haemophilus Influenzae Type B)
  • 8.8. Polio
  • 8.9. Rotavirus
  • 8.10. Varicella

9. Disease wise - Immunization Profile

  • 9.1. Immunization Coverage (%) in Infants
  • 9.2. Global Immunization Profile
  • 9.3. Regional Immunization Profile
    • 9.3.1. Measles-Number of Reported Cases
    • 9.3.2. Mumps-Number of Reported Cases
    • 9.3.3. Rubella-Number of Reported Cases
    • 9.3.4. Rubella (CRS)-Number of Reported Cases
    • 9.3.5. Diphtheria-Number of Reported Cases
    • 9.3.6. Tetanus (Neonatal)-Number of Reported Cases
    • 9.3.7. Tetanus (Total)-Number of Reported Cases
    • 9.3.8. Pertussis-Number of Reported Cases
    • 9.3.9. Polio-Number of Reported Cases
    • 9.3.10. Yellow Fever-Number of Reported Cases
    • 9.3.11. Japanese encephalitis-Number of Reported Cases

10. Vaccines Key Players Sales (2011-2024)

  • 10.1. GlaxoSmithKline, plc.'s Vaccines Sales
  • 10.2. Merck & Co. Vaccines Sales
  • 10.3. Sanofi Pasteur's Vaccines Sales
  • 10.4. Pfizer, Inc.'s Vaccines Sales
  • 10.5. Global-Other Companies Vaccines Sales

11. Vaccines-Products and Pipeline

  • 11.1. GSK Vaccine Product Pipeline
  • 11.2. Merck Vaccine Product Pipeline
  • 11.3. Sanofi Vaccine Product Pipeline
  • 11.4. Pfizer Vaccine Product Pipeline

12. Top Mergers and Acquisitions in the Vaccine Industry

13. Vaccines and Regulator's Interventions

  • 13.1. Making and Meeting Standards of Quality and Safety
  • 13.2. Vaccine Funding

14. Vaccine Market Drivers

  • 14.1. Inclusion in National Immunization Schedule
  • 14.2. Growing Immunization Coverage for HPV Vaccines
  • 14.3. Increase in Prevalence of Infectious Diseases
  • 14.4. Global Immunization Vision and Strategy (GIVS)
  • 14.5. GAVI Model Fuelling Vaccine Manufacturers
    • 14.5.1. The Partnership Model
    • 14.5.2. The Business Model
  • 14.6. Increasing Vaccine Availability in United States
  • 14.7. The Vaccine Safety Data link Project
  • 14.8. The Vaccine Injury Compensation Program
  • 14.9. Transforming of Vaccine Technologies
  • 14.10. Global Vaccine Action Plan by WHO (2011-2020)
  • 14.11. Continuous Focus on Effective Communication Strategies

15. Vaccines Market Challenges

  • 15.1. Hurdles to Optimal use of Licensed Vaccines
    • 15.1.1. Technical Obstacles
    • 15.1.2. Economic Obstacles
    • 15.1.3. Cultural Obstacles
  • 15.2. Complexity of Vaccine Development & Approval System Thwarts Product Development
    • 15.2.1. Legal Obstacles
    • 15.2.2. General Technical Barriers
    • 15.2.3. Economic Barriers
    • 15.2.4. Regulatory Barriers
  • 15.3. Shortening the Timeline for Vaccine Development
  • 15.4. Refusal/Resistance to Vaccination
    • 15.4.1. Vaccine Adverse Event Reporting System
  • 15.5. Vaccine Shortages and Delays
  • 15.6. Obstacles in Vaccine Research & Development
  • 15.7. Barriers to New Entrants in the Vaccines Market

Lists of Figures:

  • Figure 2-1: Global - Pediatric (Infant) Vaccines Market (Billion US$), 2011 - 2017
  • Figure 2-2: Global - Forecast for Pediatric (Infant) Vaccines Market (Billion US$), 2018 - 2024
  • Figure 3-1: Global - Pediatric (Infant) Vaccines Market Share (Percent), 2011 - 2017
  • Figure 3-2: Global - Forecast for Pediatric (Infant) Vaccines Market Share (Percent), 2018 - 2024
  • Figure 3-3: Global - Vaccinated Infant (Pediatric) Share (Percent), 2011 - 2017
  • Figure 3-4: Global - Forecast for Vaccinated Infant (Pediatric) Share (Percent), 2018 - 2024
  • Figure 3-5: Global - Doses of Vaccines Administered to Pediatric (Infant) Share (Percent), 2011 - 2017
  • Figure 3-6: Global - Forecast for Doses of Vaccines Administered to Pediatric (Infant) Share (Percent), 2018 - 2024
  • Figure 3-7: Global - Key Players Vaccines Market Share (Percent), 2011 - 2017
  • Figure 3-8: Global - Forecast for Key Players Vaccines Market Share (Percent), 2018 - 2024
  • Figure 4-1: Global - Number of Vaccinated Infant (Pediatric) (Million), 2011 - 2017
  • Figure 4-2: Global - Forecast for Number of Vaccinated Infant (Pediatric) (Million), 2018 - 2024
  • Figure 5-1: Global - Doses of Pediatric (Infant) Vaccines Administered (Million), 2011 - 2017
  • Figure 5-2: Global - Forecast for Doses of Pediatric (Infant) Vaccines Administered (Million), 2018 - 2024
  • Figure 6-1: Influenza - Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2017
  • Figure 6-2: Influenza - Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2024
  • Figure 6-3: MMR - Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2017
  • Figure 6-4: MMR - Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2024
  • Figure 6-5: Pneumococcal - Pediatric (Infant) Vaccines Market (Billion US$), 2011 - 2017
  • Figure 6-6: Pneumococcal - Forecast for Pediatric (Infant) Vaccines Market (Billion US$), 2018 - 2024
  • Figure 6-7: Areas with frequent epidemics of meningococcal meningitis
  • Figure 6-8: Meningococcal - Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2017
  • Figure 6-9: Meningococcal - Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2024
  • Figure 6-10: Hepatitis - Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2017
  • Figure 6-11: Hepatitis - Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2024
  • Figure 6-12: DTaP - Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2017
  • Figure 6-13: DTaP - Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2024
  • Figure 6-14: Haemophilus Influenzae Type B (HIB) - Vaccines Market (Million US$), 2011 - 2017
  • Figure 6-15: Haemophilus Influenzae Type B (HIB) - Forecast for Vaccines Market (Million US$), 2018 - 2024
  • Figure 6-16: Combos (Combination) - Vaccines Market (Billion US$), 2011 - 2017
  • Figure 6-17: Combos (Combination) - Forecast for Vaccines Market (Billion US$), 2018 - 2024
  • Figure 6-18: Polio - Vaccines Market (Million US$), 2011 - 2017
  • Figure 6-19: Polio - Forecast for Vaccines Market (Million US$), 2018 - 2024
  • Figure 6-20: Rotavirus Deaths Under Five Years of Age per 100 000 Population <5 Years of Age, 2013
  • Figure 6-21: Ten Countries Accounting for Almost Two Thirds of All Deaths, 2013
  • Figure 6-22: Rotavirus - Vaccines Market (Million US$), 2011 - 2017
  • Figure 6-23: Rotavirus - Forecast for Vaccines Market (Million US$), 2018 - 2024
  • Figure 6-24: Varicella - Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2017
  • Figure 6-25: Varicella - Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2024
  • Figure 7-1: Influenza - Number of Vaccinated Infants (Million), 2011 - 2017
  • Figure 7-2: Influenza - Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
  • Figure 7-3: MMR - Number of Vaccinated Infants (Pediatric) (Million), 2011 - 2017
  • Figure 7-4: MMR - Forecast for Number of Vaccinated Infants (Pediatric) (Million), 2018 - 2024
  • Figure 7-5: Pneumococcal - Number of Vaccinated Infants (Million), 2011 - 2017
  • Figure 7-6: Pneumococcal - Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
  • Figure 7-7: Meningococcal - Number of Vaccinated Infants (Million), 2011 - 2017
  • Figure 7-8: Meningococcal - Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
  • Figure 7-9: Hepatitis - Number of Vaccinated Infants (Million), 2011 - 2017
  • Figure 7-10: Hepatitis - Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
  • Figure 7-11: DTaP - Number of Vaccinated Infants (Million), 2011 - 2017
  • Figure 7-12: DTaP - Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
  • Figure 7-13: Hib (Haemophilus Influenzae Type B) - Number of Vaccinated Infants (Million), 2011 - 2017
  • Figure 7-14: Hib (Haemophilus Influenzae Type B) - Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
  • Figure 7-15: Combos (Combination Vaccines) - Number of Vaccinated Infants (Million), 2011 - 2017
  • Figure 7-16: Combos (Combination Vaccines) - Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
  • Figure 7-17: Polio - Number of Infants Immunized (Million), 2011 - 2017
  • Figure 7-18: Polio - Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
  • Figure 7-19: Rotavirus - Number of Infants Immunized (Million), 2011 - 2017
  • Figure 7-20: Rotavirus - Forecast for Number of Infants Immunized (Million), 2018 - 2024
  • Figure 7-21: Varicella - Number of Vaccinated Infants (Million), 2011 - 2017
  • Figure 7-22: Varicella - Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
  • Figure 8-1: Influenza - Doses of Infant Vaccines Administered (Million), 2011 - 2017
  • Figure 8-2: Influenza - Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
  • Figure 8-3: MMR - Doses of Infant Vaccines Administered (Million), 2011 - 2017
  • Figure 8-4: MMR - Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
  • Figure 8-5: Pneumococcal - Doses of Infant Vaccines Administered (Million), 2011 - 2017
  • Figure 8-6: Pneumococcal - Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
  • Figure 8-7: Meningococcal - Doses of Infant Vaccines Administered (Million), 2011 - 2017
  • Figure 8-8: Meningococcal - Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
  • Figure 8-9: Hepatitis - Doses of Infant Vaccines Administered (Million), 2011 - 2017
  • Figure 8-10: Hepatitis - Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
  • Figure 8-11: DTaP - Doses of Infant Vaccines Administered (Million), 2011 - 2017
  • Figure 8-12: DTaP - Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
  • Figure 8-13: Hib (Haemophilus Influenzae Type B) - Doses of Infant Vaccines Administered (Million), 2011 - 2017
  • Figure 8-14: Hib (Haemophilus Influenzae Type B) - Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
  • Figure 8-15: Polio - Doses of Infant Vaccines Administered (Million), 2011 - 2017
  • Figure 8-16: Polio - Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
  • Figure 8-17: Rotavirus - Doses of Infant Vaccines Administered (Million), 2011 - 2017
  • Figure 8-18: Rotavirus - Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
  • Figure 8-19: Varicella - Doses of Infant Vaccines Administered (Million), 2011 - 2017
  • Figure 8-20: Varicella - Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
  • Figure 10-1: Global - GlaxoSmithKline, plc.'s Vaccines Sales (Billion US$), 2011 - 2017
  • Figure 10-2: Global - Forecast for GlaxoSmithKline, plc.'s Vaccines Sales (Billion US$), 2018 - 2024
  • Figure 10-3: Global - Merck & Co. Vaccines Sales (Billion US$), 2011 - 2017
  • Figure 10-4: Global - Forecast for Merck & Co. Vaccines Sales (Billion US$), 2018 - 2024
  • Figure 10-5: Global - Sanofi Pasteur's Vaccines Sales (Billion US$), 2011 - 2017
  • Figure 10-6: Global - Forecast for Sanofi Pasteur's Vaccines Sales (Billion US$), 2018 - 2024
  • Figure 10-7: Global - Pfizer, Inc.'s Vaccines Sales (Billion US$), 2011 - 2017
  • Figure 10-8: Global - Forecast for Pfizer, Inc.'s Vaccines Sales (Billion US$), 2018 - 2024
  • Figure 10-9: Global - Other Companies Vaccines Sales (Billion US$), 2011 - 2017
  • Figure 10-10: Global - Forecast for Other Companies Vaccines Sales (Billion US$), 2018 - 2024
  • Figure 11-1: GSK Vaccine Product Pipeline
  • Figure 14-1: Countries with HPV Vaccination Program listed on their National Immunization Program (NIP) Schedule
  • Figure 14-2: Number of Cases of Diphtheria, Pertussis, Tetnaus & Measles by Major Region Worldwide, 2013
  • Figure 14-3: Vaccines Procured by UNICEF: Industrialized and Emerging Market Country Manufacturers
  • Figure 14-4: Vaccines procured by UNICEF: Industrialized and Emerging Market Country Manufacturers
  • Figure 14-5: US Retail Clinics Expected to Surge by 2017

Lists of Tables:

  • Table 9-1: Worldwide Immunization Coverage (%) in Infants, 2005- 2010
  • Table 9-2: Worldwide Immunization Coverage (%) in Infants, 2011- 2016
  • Table 9-3: Vaccines - Number of Reported Cases, 2011 - 2017
  • Table 9-4: Measles - Number of Reported Cases, 2001 - 2016
  • Table 9-5: Mumps - Number of Reported Cases, 2001 - 2016
  • Table 9-6: Rubella - Number of Reported Cases, 2001 - 2016
  • Table 9-7: Rubella (CRS) - Number of Reported Cases, 2001 - 2016
  • Table 9-8: Diphtheria - Number of Reported Cases, 2001 - 2016
  • Table 9-9: Tetanus (Neonatal) - Number of Reported Cases, 2001 - 2016
  • Table 9-10: Tetanus (Total) - Number of Reported Cases, 2001 - 2016
  • Table 9-11: Pertussis - Number of Reported Cases, 2001 - 2016
  • Table 9-12: Polio - Number of Reported Cases, 2001 - 2016
  • Table 9-13: Yellow Fever - Number of Reported Cases, 2001 - 2016
  • Table 9-14: Japanese Encephalitis - Number of Reported Cases Reported, 2006 - 2016
  • Table 11-1: Merck Vaccine Product Pipeline
  • Table 11-2: Sanofi Vaccine Product Pipeline
  • Table 11-3: Pfizer Vaccine Product Pipeline
  • Table 12-1: Vaccine Mergers & Acquisitions
  • Table 14-1: United States Immunization Schedule
  • Table 14-2: Afghanistan Immunization Schedule
  • Table 14-3: Norway Immunization Schedule
  • Table 14-4: India Immunization Schedule
  • Table 14-5: Vietnam Immunization Schedule
  • Table 14-6: Worldwide - Total Future Deaths Averted through Vaccination (Million), 2011 - 2020
  • Table 14-7: Goal-Level Indicators, 2015 & 2020
  • Table 14-8: Improvement Strategies or Requirements - the Joint Commission and the Project's Collaborating Organizations